Samumed to announce potential disease modifying treatment of osteoarthritis at ACR 2015

SAN DIEGO — Nov. 3, 2015 — Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

Specifically, Samumed will present preclinical research results that demonstrate cartilage regeneration in an animal model of OA after a single intra-articular injection of SM04690 in an oral presentation. In addition, Samumed will present two posters that detail interim safety, pK, efficacy and radiographic imaging results (MRI and X-ray), respectively, from a now-completed 24-week placebo-controlled, double-blind, randomized Phase I clinical trial of SM04690 in patients with moderate to severe osteoarthritis of the knee.

"Our technology platform focuses on small molecule drugs that repair/regenerate local tissue. To date, we have four compounds in clinical trials, targeting five disease areas that impact the health and quality-of-life of millions of people. We will continue to expand our pipeline, as well as share data from our programs with the scientific and medical community," said Osman Kibar, Ph.D., Chief Executive Officer and Founder of Samumed.

###

SAMUMED'S ACR 2015 ABSTRACTS

Posters

Sunday, Nov. 8, 2015; 8:30am — 4:00pm

Poster #312 & #313

Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Session Title: Osteoarthritis — Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690)
in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results
from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

Session Title: Osteoarthritis — Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Presentation

Monday, Nov. 9, 2015; 2:30pm — 4:00pm

Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway
(SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis

Session Title: Biology and Pathology of Bone and Joint: Osteoarthritis Pathogenesis

ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous disease areas where modulating the Wnt pathway to repair/regenerate tissue could have a therapeutic effect. This technology platform has the potential to improve the treatment of numerous degenerative diseases like osteoarthritis, degenerative disc disease and pulmonary fibrosis, as well as many forms of cancer. The company currently has four compounds across five disease areas in clinical trials.